Novo Nordisk Invests US$1.8 billion for New Drug Plant in Missouri, USA
Introduction:
Novo Nordisk plans to invest US$1.8 billion in the construction of a new pharmaceutical manufacturing facility in Missouri, USA.
Features:
A state-of-the-art facility spanning 833,000 square feet, with a footprint covering 417,639 square feet an area roughly equivalent to seven football fields.
This cutting-edge facility will specialise in the production of active pharmaceutical ingredients (API) for a diverse portfolio of current and future glucagon-like peptide-1 (GLP-1) and insulin-based medications.
Once fully operational in 2020, the facility will significantly enhance production capacity, ensuring a robust supply of diabetes treatments.
The existing 457,000-square-foot Clayton plant, the new facility builds on the company’s longstanding presence in the region.
The addition of the new facility not only expands the physical footprint but also strengthens its workforce, reinforcing its position in biomanufacturing.
This strategic expansion highlights its dedication to advancing healthcare solutions and maintaining its leadership in the biopharmaceutical industry.
Specifications:
Name : Novo Nordisk
Type : New Construction
Budget : US$1.8 billion
